1 - 10 of 85 Search Results for 577
|
|
|
1.
OPSL-532/577 Lasers
|
|
OPSL-532/577 Lasers OPS Lasers designed for laser photocoagulation treatment of wet-form macular degeneration Superior Reliability & Performance Lasers and Laser-based Systems Laser Measurement and Control Precision Optics Related Accessories The OPSL-532/577 family of lasers, designed for laser ...
Related Searches: opsl | diabetic retinopathy | 577nm
|
|
|
|
|
2.
OPSL-532/577 Lasers
|
|
OPSL-532/577 Lasers OPS Lasers designed for laser photocoagulation treatment of wet-form macular degeneration Coherent's line of OPS Lasers: OPSL-577 OPSL-532 Sapphire Lasers TracER Forensic Laser System Venom Entertainment Lasers The OPSL-532/577 family of lasers, designed for laser photocoagulation ...
Related Searches: ops | opsl | 577nm | photocoagulation
|
|
|
|
|
3.
Medical Applications
|
|
... Degeneration Skin resurfacing Surgical applications Coherent was recently awarded the 2008 PhAST Laser Focus World Innovation Award for our OPSL-577-3 Optically Pumped Semiconductor Laser. This laser was specifically developed to meet the challenges for effective laser treatment of diseases such as ...
Related Searches: laser medical application | photocoagulation
|
|
|
|
4.
Coherent_2007
(PAGE 32 OF 162)
|
|
|
... 1,261,297 372,329 97,564(3)$ 2,559,027 Helene Simonet, Executive Vice President and Chief Financial Officer 2007 351,719 115,647 493,108 171,933 53,577(4)$ 1,185,984 Luis Spinelli, Executive Vice President and Chief Technology Officer 2007 250,759 45,159 203,860 90,677 63,447(5)$ 653,902 Ronald A. Victor ...
|
|
|
|
|
5.
Coherent
(PAGE 104 OF 156)
|
|
|
... $ 681 $ 980 Gain on sale of interest in joint venture . 1,065 - Net gain (loss) on sale of assets . 1 291 (3) Equity in loss of joint ventures . (1,577) (2,817) (1,927) Gain on investments, net . 1,724 1,213 3,105 Customer contract settlement fee . 4,400 Other -- net . 222 1,856 802 Other income (expense ...
|
|
|
|
|
6.
Coherent
(PAGE 105 OF 156)
|
|
|
... Deferred tax assets: Reserves and accruals not currently deductible . $ 19,019 $ 25,140 Operating loss carryforwards and tax credits . 47,491 40,577 Capital loss carryforwards . 21,486 22,031 Asset impairment . 7,351 7,400 Intercompany profit . 4,777 2,505 Deferred service revenue . 1,348 1,220 Depreciation ...
|
|
|
|
|
7.
Coherent
(PAGE 107 OF 156)
|
|
|
... 3,048 -- 3,102 Gross profit . 191,718 25,951 -- 217,669 Research & development . 45,198 12,347 -- 57,545 In-process research and development . 1,577 -- 1,577 Selling, general & administrative . 96,101 18,583 1,143 115,827 Restructuring, impairment and other charges (recoveries) . (61) - (61 ...
|
|
|
|
|
8.
Entertainment and Display
|
|
... for the entertainment industry - our Venom family of entertainment lasers.These high power OPSL's have wavelenghts of 532 nm (Green) and 577 nm (Yellow). With power configurations of 5W and 8W at 532 nm, and 3W at 577 nm, and our newest offering, 2W at 460 nm (Blue), this wavelength ...
Related Searches: viper | star | venom | star c
|
|
|
|
|
9.
Coherent
(PAGE 110 OF 156)
|
|
|
... ENDED SEPTEMBER 30, 2005: Net sales . $126,022 $131,175 $125,269 $133,786 Gross profit . 51,536(1) 58,487 56,680 50,966(1) Net income . 5,388(2) 19,577(2) 9,645(2) 5,251 Net income per basic share . $ 0.18 $ 0.64 $ 0.31 $ 0.17 Net income per diluted share . $ 0.17 $ 0.63 $ 0.31 $ 0.17 YEAR ENDED SEPTEMBER ...
|
|
|
|
|
10.
CompactSourcesGiveBespokeWavelengths
(PAGE 3 OF 3)
|
|
|
... oxyhaemoglobinactuallypeaksat577nm (see figure 3). Coherent has designed a new OPSL for this application (the OPSL-577-3) which delivers 3 W of output power at 577 nm. At a very minimum, this improves vessel closure with reduced thermal loading on the eye but beyond this important benefit, the fast ...
|
|
Coherent Contact Information